Clinical trial NCT02728700 (phase 1, status: terminated)
Conditions: adult hodgkin lymphoma, adult myelodysplastic syndrome, blast phase chronic myelogenous leukemia, bcr-abl1 positive, childhood chronic myelogenous leukemia, bcr-abl1 positive, childhood hodgkin lymphoma, childhood myelodysplastic syndrome, chronic phase chronic myelogenous leukemia, bcr-abl1 positive, myelofibrosis, primary myelofibrosis, recurrent adult acute lymphoblastic leukemia, recurrent adult acute myeloid leukemia, recurrent adult non-hodgkin lymphoma, recurrent childhood acute lymphoblastic leukemia, recurrent childhood acute myeloid leukemia, recurrent childhood non-hodgkin lymphoma, recurrent chronic myelogenous leukemia, bcr-abl1 positive, refractory chronic myelogenous leukemia, bcr-abl1 positive, refractory non-hodgkin lymphoma
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01, F80.81, F84.3, F93.8, F93.9, R62.0, E71.520, F64.2, D46.Z, D46.9, C94.6, D46.C, C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01, D75.81, C94.41, C94.42, C94.40, D75.81, C94.41, C94.42, C94.40, C83.57, C83.50, C91.01, C91.02, C83.52, C83.56, C83.53, G47.13, J01.41, K11.22, K12.0, N96, F33.8, G03.2, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, C83.57, C83.50, C91.01, C91.02, C83.52, C83.56, C83.53, G47.13, J01.41, K11.22, K12.0, N96, F33.8, G03.2, G47.13, J01.41, K11.22, K12.0, N96, F33.8, G03.2
Drugs: mycophenolate mofetil, sirolimus
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2
Reason stopped: 
    accrual factor
  
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects must have one of the following disease categories:

               -  Acute myeloid leukemia (AML) beyond 2nd remission or relapsed/refractory disease

               -  Acute lymphoblastic leukemia (ALL) beyond 2nd remission or relapsed/refractory
                  disease

               -  Chronic myeloid leukemia (CML) beyond 2nd chronic phase or in blast crises

               -  Myelodysplastic syndrome (MDS)

               -  Myeloproliferative disorders including myeloid metaplasia and myelofibrosis

               -  High risk non-Hodgkin's lymphoma (NHL) in first remission

               -  Relapsed or refractory NHL

               -  Hodgkin's lymphoma (HL) beyond first remission

          -  Performance status by Karnofsky of >= 70% or Lansky > 70% for patients < 16 years of
             age

          -  Human leukocyte antigen (HLA) mismatched related or unrelated donor identified 8/10 or
             9/10

          -  Willingness to take oral medications during the transplantation period

          -  Willingness and ability to sign a written informed consent (assent if applicable)

        Exclusion Criteria:

          -  Prior myeloablative allogeneic or autologous HSCT

          -  Human immunodeficiency virus (HIV) infection

          -  Pregnant or lactating females

          -  Evidence of uncontrolled active infection

          -  Down syndrome

          -  Serum creatinine (CR) < 1.5mg/dl or 24 hour CR clearance < 50 ml/min

          -  Direct bilirubin > 2 x upper limit of normal (ULN)

          -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2 x ULN

          -  Carbon monoxide diffusing capability test (DLCO) > 60% predicted and in children- room
             air oxygen saturation > 92%

          -  Left ventricular ejection fraction < 45% and in children-shortening fraction < 26%

          -  Fasting cholesterol > 300 mg/dl or triglycerides > 300 while on lipid lowering agents

          -  Patients who have received an investigational drug within 30 days of enrollment in
             study

          -  Patients with prior malignancies except basal cell carcinoma or treated carcinoma
             in-situ; cancer treated with curative intent > 5 years will be allowed; cancer
             treatment with curative intent =< 5 years will not be allowed